Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN versus VANTAS.
SUPPRELIN vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist